Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.007 USD | +2.22% |
|
+6.57% | -14.75% |
06-24 | Transcript : Aprea Therapeutics, Inc. - Special Call | |
06-17 | Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.75% | 21.29M | |
+25.40% | 46.56B | |
+45.38% | 41.67B | |
+0.96% | 41.16B | |
+30.52% | 32.4B | |
+22.39% | 28.18B | |
-6.35% | 28.1B | |
+48.81% | 14.52B | |
+48.55% | 13.74B | |
+3.40% | 12.17B |
- Stock Market
- Equities
- APRE Stock
- News Aprea Therapeutics, Inc.
- Transcript : Aprea Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-13-2022 11